Major Cardiovascular Events and Biologics: What’s The Risk?
Major adverse cardiovascular events (MACEs), such as myocardial infarction, cerebrovascular accident or cardiovascular death, have been associated with use of biologics in patients with moderate-to-severe psoriasis, but the link is unclear. A recent meta-analysis looked at 38 randomized controlled trials (RCTs) to examine the risk of MACEs in adult patients with plaque psoriasis that are exposed to biologic therapies. This was the largest meta-analysis to date and includes the newest biologics approved to treat plaque psoriasis.
There were 10 MACEs during the randomized controlled phase in nine of the studies, and no observed MACEs in 27 other RCTs. The results showed no statistically significant difference in the risk of MACEs in patients with plaque psoriasis exposed to biologic therapies compared with placebo.
The authors note that they did not study one biologic treatment that has been previously associated with an increased MACE risk, briakinumab, because the treatment has not been approved yet by the regulatory agencies. They also emphasize that there are other limitations of their meta-analysis that include the use of RCTs with small sample size and short duration of the randomized controlled treatment phase. However, despite these limitations they conclude that the existing evidence suggests that biologic therapies had no significant impact on the risk of MACEs in adult patients with plaque psoriasis over the short term.
Byline: Martha L. Sikes, MS, RPh, PA-C
Posted: May 22, 2017
Source: Wiley Online Library
Adapted from the original article.